From: Increased incidence of autoimmune markers in patients with combined pulmonary fibrosis and emphysema
Characteristics | CPFE baseline data | IPF baseline data |
---|---|---|
Subjects | 40 | 60 |
Male | 38 | 49 |
Age (yrs) | 56 (31–74) | 66 (44 – 78) |
Current smokers | 2 | 0 |
Ex-smokers | 38 | 60 |
Steroid treatment | 18 | 22 |
Bronchodilators | 15 | 0 |
NAC | 37 | 43 |
Pirfenidone | 30 | 23 |
Cyclophosphamide | 3 | 0 |
Azathioprine | 7 | 11 |
VATS | 15 | 28 |
FEV1 %predicted | 68,6 ± 19 | 67,8 ± 9,1 |
FVC %predicted | 70,6 ± 21* | 62,8 ± 11,4 |
FEV1/FVC | 77,6 ±11,2 | 83,2 ±10,1 |
TLC %predicted | 69,7 ± 17,9* | 57,1 ± 9,1 |
DLCO %predicted | 34,8 ±15* | 44,1 ±7,2 |
MMEF25/75%predicted | 69,3 ±35* | 79,8 ±19 |
6MWD (m) | 330 ± 168* | 402 ± 112 |
sPAP (by echocardiography) mmHg | 37,3 ± 14,5* | 32,1 ± 10,9 |